Edition:
India

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

4.20USD
15 Jun 2018
Change (% chg)

$0.08 (+1.82%)
Prev Close
$4.12
Open
$4.15
Day's High
$4.28
Day's Low
$4.15
Volume
53,667
Avg. Vol
62,874
52-wk High
$5.75
52-wk Low
$1.58

Latest Key Developments (Source: Significant Developments)

Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures
Wednesday, 23 May 2018 

May 23 (Reuters) - AcelRx Pharmaceuticals Inc ::THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES.ACELRX PHARMACEUTICALS INC - NO CHANGES WERE MADE TO COMPOSITION OR SIZE OF ACELRX'S BOARD OF DIRECTORS.ACELRX PHARMACEUTICALS - ALL OF CO'S SHARES OWNED BY THREE ARCH ACQUIRED BY INVESTORS LED BY LEERINK REVELATION PARTNERS, INDUSTRY VENTURES.ACELRX PHARMACEUTICALS INC - REMAIN ON TRACK TO ACHIEVE REMAINING KEY MILESTONES THIS YEAR.ACELRX PHARMACEUTICALS INC - THREE ARCH FUNDS IN DISSOLUTION PROCESS AND ARE EACH FINALIZING LIQUIDATION OF THEIR ENTIRE RESPECTIVE PORTFOLIOS.ACELRX PHARMACEUTICALS INC - THREE ARCH FUNDS REMAINING ASSETS COMPRISED OF 9.4 MILLION SHARES IN AGGREGATE ACROSS ALL OF FUNDS.  Full Article

Acelrx Pharmaceuticals posts Q3 loss of $0.28 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Acelrx Pharmaceuticals Inc :Acelrx pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.28.Q3 revenue $1.5 million.Q3 revenue view $2.2 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Acelrx pharmaceuticals - $67.9 million of cash and cash equivalents at Sseptember 30, 2017​.  Full Article

AcelRx Pharma receives Complete Response Letter from the FDA for Dsuvia™ NDA
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Acelrx Pharmaceuticals Inc :AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for Dsuvia™ NDA.AcelRx - ‍CRL states that FDA determined it cannot approve NDA in its present form and provides recommendations needed for resubmission​.AcelRx Pharmaceuticals Inc - ‍confirm plans to move towards resubmission of Dsuvia NDA​.AcelRx Pharmaceuticals Inc - ‍AcelRx ended Q3 with an estimated $67.9 million in cash and we will provide further financial updates on our Q3 earnings call​.AcelRx Pharmaceuticals-will request a meeting with FDA to discuss topics covered in CRL.AcelRx Pharmaceuticals Inc - ‍ received a complete response letter from FDA regarding its new drug application for Dsuvia, 30 MCG​.AcelRx - in CRL, collection of additional data requested on at least 50 patients to assess safety of dsuvia dosed at maximum amount set in proposed labelling​.AcelRx Pharmaceuticals Inc - ‍in CRL, FDA recommended certain changes to directions for use to address use-related errors, including dropped tablets​.  Full Article

Acelrx Pharmaceuticals submits drug application for acute pain treatment
Tuesday, 13 Dec 2016 

Acelrx Pharmaceuticals Inc : Acelrx Pharmaceuticals submits new drug application for ARX-04 for the treatment of moderate-to-severe acute pain .Using NDA for marketing authorization application for ARX-04 to european medicines agency with target submission date in H1 2017.  Full Article

Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc
Tuesday, 4 Oct 2016 

Acelrx Pharmaceuticals Inc : Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing .On September 30, co amended loan and security deal with Hercules Technology II, L.P. and Hercules Capital, Inc..  Full Article

Acelrx Pharmaceuticals Q2 loss per share $0.24
Friday, 29 Jul 2016 

Acelrx Pharmaceuticals Inc : Acelrx Pharmaceuticals provides corporate update and reports second quarter and six months 2016 financial results . Q2 loss per share $0.24 .Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article

Acelrx Pharmaceuticals says start date for IAP312 study revised
Friday, 8 Jul 2016 

Acelrx Pharmaceuticals Inc: Acelrx Pharmaceuticals Inc says has finalized certain modifications to the Zalviso device and pending receipt of the devices from the manufacturer . Says on July 6, 2016, the start date for the IAP312 study was revised to September 2016 - SEC filing .Start date for study may be delayed if devices received from manufacturer do not pass final quality checks, certain release specifications.  Full Article